Recent Conference Presentations

  1. Oran B, Ciurea S, Marin D, et al. Safety Analysis of Intra-Patient Dose-Study Of Crenolanib Maintenance Therapy In Patients With Flt3 Mutant Aml Following Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct). EBMT-1317 (2019).
  2. Goldberg AD, Collins RH, Stone RM, et al. Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co-Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML. ASH-1436 (2018).
  3. Oran B, Ciurea S, Marin D, et al. Safety Analysis of Intra-Patient Dose- Study Of Crenolanib Maintenance Therapy In Patients With Flt3 Mutant Aml Following Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct). ASH-3426 (2018).
  4. Dalle IA, Kantarjian H, Ohanian M, et al. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. ASH-2715 (2018).
  5. Walter R, Collins R, Stone R, et al. Addition Of Crenolanib To Standard Induction And Consolidation Therapies Improved Long-Term Outcomes In Newly Diagnosed Flt3-Mutant Aml Patients ≤ 60 Years Old. EHA-1908 (2018).
  6. Oran B, Ciurea S, Marin D, et al. Intra-Patient Dose-Escalation Study Of Crenolanib Maintenance Therapy In Patients With Flt3 Mutant Aml Who Had Undergone Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct). EHA-3798 (2018).
  7. Tarlock K, Hylkema T, Pollard J, et al. Functional Assessment of Novel Diagnostic FLT3 Mutations and Inhibition by Kinase Inhibitors. Haematologica; 2017; 2017. p. 40-1.
  8. Wang E, Stone R, Collins R, Agrawal T, Urity V, Tallman M. Variant FLT3 Mutations Can be Eridicated by Cytarabine/Anthracycline/Crenolanib Induction in Adult Patients with Newly Diagnosed FLT3 (ITD/TKD) Mutant AML.  Haematologica; 2017; 2017. p. 212.
  9. Stone RM, Collins R, Tallman MS, et al. Effect of Cytarabine/Anthracycline/Crenolanib Induction on Minimal Residual Disease (MRD) in Newly Diagnosed FLT3 Mutant AML. J Clin Oncol 2017; 35(15_suppl): 7016.
  10. Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib Besylate, a Type I Pan-FLT3 Inhibitor, to Demonstrate Clinical Activity in Multiply Relapsed FLT3-ITD and D835 AML. J Clin Oncol 2016; 34 (suppl; abstr 7008).
  11. Wang, E.S., et al., Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). Blood, 2016. 128(22): p. 1071-1071.
  12. Ohanian, M., et al., Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood, 2016. 128(22): p. 2744-2744.
  13. Iyer, S.P., et al., Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. Blood, 2016. 128(22): p. 3983-3983.
  14. Inaba, H., et al., Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 2016. 128(22): p. 3937-3937.
  15. Zhang, H., et al., Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib. Blood, 2015. 126(23): p. 2468-2468.
  16. Panetta, J.C., et al., Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood, 2015. 126(23): p. 3695-3695.
  17. Collins, R., et al., Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant. Blood, 2015. 126(23): p. 4359-4359.
  18. Collins R, Kantarjian HM, Levis MJ, et al. Clinical Activity Of Crenolanib In Patients With D835 Mutant FLT3-Positive Relapsed/Refractory Acute Myeloid Leukemia (AML). J Clin Oncol 2014; 32:5s (suppl; abstr 7027).

Leave a Reply

Your email address will not be published. Required fields are marked *